Comparative Pharmacology
Head-to-head clinical analysis: INVEGA TRINZA versus REXULTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA TRINZA versus REXULTI.
INVEGA TRINZA vs REXULTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 3 to 6 months (mean 118 days) due to slow dissolution from intramuscular depot; clinical context: steady state reached after 3 injections every 3 months.
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Renal: 59-80% as unchanged drug and metabolites; fecal: 6-15%; biliary: minimal.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic